Vectibix misses OS endpoint for mCRC

Amgen Inc. (NASDAQ:AMGN) said first-line Vectibix panitumumab plus FOLFOX4 chemotherapy missed the secondary endpoint of significantly improving overall survival in patients with wild-type K-Ras (KRAS) vs. FOLFOX4 alone in the Phase III PRIME trial to treat metastatic colorectal cancer (23.9 vs. 19.7 months, p=0.072). Amgen said Vectibix plus chemotherapy non-significantly reduced OS in patients with tumors containing activating K-Ras mutations compared with chemotherapy alone. Amgen was up $1.93 to $54.05 on Thursday. ...